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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.029In normal rat liver, thymocyte antigen 1 (Thy1) is expressed in ﬁbroblasts/myoﬁbroblasts and in some
blood progenitor cells. Thy1-expressing cells also accumulate in the liver during impaired liver
regeneration. The origin and nature of these cells are not well understood. By using RT-PCR analysis and
immunoﬂuorescence microscopy, we describe the presence of rare Thy1þ cells in the liver lobule of
normal animals, occasionally forming small collections of up to 20 cells. These cells constitute a small
portion (1.7% to 1.8%) of nonparenchymal cells and reveal a mixed mesenchymal-epithelial phenotype,
expressing E-cadherin, cytokeratin 18, and desmin. The most potent mitogens for mesenchymal-
epithelial Thy1þ cells in vitro are the inﬂammatory cytokines interferon g, IL-1, and platelet-derived
growth factor-BB, which are not produced by Thy1þ cells. Thy1þ cells express all typical mesen-
chymal stem cell and hepatic progenitor cell markers and produce growth factor and cytokine mRNA
(Hgf, Il6, Tgfa, and Tweak) for proteins that maintain oval cell growth and differentiation. Under
appropriate conditions, mesenchymal-epithelial cells differentiate in vitro into hepatocyte-like cells. In
this study, we show that the adult rat liver harbors a small pool of endogenous mesenchymal-epithelial
cells not recognized previously. In the quiescent state, these cells express both mesenchymal and
epithelial cell markers. They behave like hepatic stem cells/progenitors with dual phenotype, exhibiting
high plasticity and long-lasting proliferative activity. (Am J Pathol 2015, 185: 110e128; http://
dx.doi.org/10.1016/j.ajpath.2014.08.029)Supported by NIH grant R01 DK59321 (M.D.) and the Liver Pathobiology
and Gene Therapy Research Core Center of the Albert Einstein College of
Medicine grant P30 DK41296. Partly supported by funds generously provided
by NIH grant R01 DK41296 from Drs. Allan Wolkoff and David Shafritz.
Disclosures: None declared.The liver has a remarkable capacity to regenerate. In rats,
after partial hepatectomy (PH), the resident cells (hepato-
cytes, biliary epithelial cells, Kupffer cells, stellate cells, and
endothelial and sinusoidal cells) undergo one or two rounds
of cell division and restore the liver mass in 7 to 10 days.1
However, when hepatocyte function is compromised and
coupled with inability of residual hepatocytes to proliferate,
the liver restores its mass through oval cell (OC)emediated
liver regeneration. OCs behave like adult hepatic progenitor
cells; they proliferate and differentiate into hepatocytes and
cholangiocytes.2e10 OCs form pseudoducts that are in close
proximity to desmin-positive cells.11 Because OCs and
thymocyte antigen 1 (Thy1)/desmin-expressing cells are in
close contact, Thy1 was proposed as a marker of hepaticstigative Pathology.
.OCs.12 However, subsequent publications reported that in
rat liver, after 2-acetylaminoﬂuorene treatment in conjunc-
tion with PH (2-AAF/PH), Thy1 is expressed in hepatic
myoﬁbroblasts.13,14
Thy1 is a cell surface glycophosphatidylinositol-linked
glycoprotein with a molecular mass of 35 kDa and is an
adhesion molecule of the immunoglobulin superfamily. In
mice and rats, Thy1 is expressed in the brain, on thymocytes,
Rat Liver Mesenchymal-Epithelial CellsT lymphocytes, ﬁbroblasts, epidermal cells, and a small
population of bone marrow cells. Thy1 is involved in T-cell
activation and affects numerous nonimmunologic biological
processes, such as cellular adhesion, neurite outgrowth,
tumor growth, migration, and cell death.15,16 In the liver,
Thy1 expression was also detected in cell lines of human fetal
hepatoblasts,17 in a stem-like population (distinct from OCs),
derived from adult human liver18 and in hepatocellular car-
cinoma cell lines.19
In our previous work, we showed that in normal rat liver,
several populations of cells express Thy1: circulating blood
progenitor cells (Thy1þ/CD45þ), ﬁbroblasts in the peri-
portal region surrounding bile ducts and blood vessels, a
small population of mesenchymal cells at the lobular
interface, and cells in the liver lobule; these cells were not
described previously.20 Most Thy1þ cells located at the
lobular interface and in the parenchyma co-express desmin,
but not Acta2 [alias a-smooth muscle actin (SMA)].20
Thy1-expressing cells proliferate moderately after carbon
tetrachloride acute injury, but in all models of OC-mediated
liver regeneration, their number is increased substantially.20
RT-PCR analyses showed that activated Thy1þ cells do not
express OC genes, but they express genes known to be
expressed in mesenchymal stem cells, genes considered
speciﬁc for activated stellate cells and myoﬁbroblasts, and
growth factors and cytokines that affect OC growth.20
Subcloning of Thy1þ cells from OC-activated livers yields
Thy1þ ﬁbroblastic cells and a population of E-cadherinþ
mesenchymal-epithelial cells that express cytokeratins.20
In normal liver, Thy1-positive cells express desmin, but
not Acta2, suggesting that they are not resident myoﬁbro-
blasts or pericytes. Also, they are not portal ﬁbroblasts,
because they do not express CD39L1 and elastin.21,22 In
addition, it has been shown recently that glial ﬁbrillary
acidic protein (GFAP)eexpressing activated hepatic stellate
cells and myoﬁbroblasts in thioacetamide-induced rat liver
injury express desmin, Acta2, and vimentin, but they do not
express Thy1.23
Mesenchymal stem cells recruited from bone marrow
stroma and other adult tissues, including human liver, are of
great potential signiﬁcance for regenerative medicine. It was
recognized recently that these cells exhibit enormous plas-
ticity and, under appropriate stimuli, can differentiate not
only into osteoblasts, chondrocytes, and adipocytes, but also
into myocytes, neuronal cells, and hepatocyte-like cells,
which underlines their importance.24e27 The origin of the
small Thy1þ cells that expand quickly in the liver after
injury and disappear when the insult is resolved has not
been determined. One possibility is that they originate from
bone marrow mesenchymal cells and are attracted to the
injured liver.28,29 Another possibility is that Thy1 cells are a
subpopulation of hepatic mesenchymal cells that are acti-
vated simultaneously with OCs. If their origin is hepatic,
they may constitute a mesenchymal progenitor-like popu-
lation. Alternatively, these cells could be a product of
epithelial-mesenchymal transition.30The American Journal of Pathology - ajp.amjpathol.orgHerein, we investigated further the nature of Thy1-
expressing cells and characterized their mesenchymal-
epithelial phenotype and progenitor-like characteristics in
normal liver in vivo and in vitro and during OC-mediated
liver regeneration. We also determined whether they have
endogenous or bone marrow origin. Two models of
OC-mediated liver regeneration were used: 2-AAF/PH and
retrorsine (Rs) in conjunction with PH (Rs/PH). 2-AAF is
metabolized in the liver, causing destruction of hepatocytes,
formation of DNA adducts, and inability of residual hepa-
tocytes to proliferate when PH is performed. In this model,
massive hepatocyte proliferation begins after termination of
the 2-AAF diet, and the liver returns to normal appearance
within 14 days.31 Rs is a member of the pyrrolizidine alkaloid
family that blocks hepatocyte division and induces mega-
locytosis; its exact mechanism of action remains unclear.
Rs exerts a strong and persistent cell cycle block (G1, S, and/
or late G2). When PH is performed, liver regeneration re-
mains incomplete, even after 16 weeks.32
Materials and Methods
Chemicals
All chemicals, including lipopolysaccharides (LPSs), were
from Sigma (St. Louis, MO), unless otherwise stated.
Cytokines and Mitogens
Recombinant rat interferon-gamma (IFN-g); recombinant
human IL-1a (carrier free); recombinant rat IL-1b; recombinant
rat epidermal growth factor (EGF); recombinant human acidic
ﬁbroblast growth factor (FGF-1); recombinant rat acidic FGF-
1; recombinant rat basic FGF-2; recombinant mouse platelet-
derived growth factor BB (PDGF-BB); recombinant rat tumor
necrosis factor a (TNF-a); recombinant rat IL-6; recombinant
human hepatocyte growth factor (HGF); and recombinant
human connective tissue growth factor (CTGF) were from
ProSpec-Tany Technogene Ltd. (Ness Ziona, Israel).
Recombinant human PDGF-BB; recombinant rat IFN-g;
recombinant human IL-1a; recombinant rat IL-1b; recom-
binant human acidic FGF-1; recombinant human FGF-2;
recombinant human TGF-b1; recombinant human FGF-4;
recombinant human EGF; recombinant human TGF-a; re-
combinant mouse IL-6 were from PeproTech Inc. (Rocky
Hill, NJ). Recombinant mouse IL-6 and recombinant human
IL-1a were from BioLegend (San Diego, CA). Recombinant
human HGF is from BioVision, Inc. (Milpitas, CA). Re-
combinant mouse HGF; recombinant human FGF-4; re-
combinant mouse PDGF-BB were from R&D Systems, Inc.
(Minneapolis, MN).
Antibodies
Primary antibodies are listed in Table 1. Anti-rabbit per-
oxidaseelinked antibody was from Amersham Biosciences111
Table 1 Primary Antibodies Used in This Study
Antibodies Isotype Company or producer Catalog no. Dilution
Mouse anti-KRT18 IgG1 Abcam (Cambridge, MA) Ab668 1:200
Rabbit anti-KRT18 Polyclonal Novus Biologicals, LLC (Littleton, CO) NBP1-67610 1:150
Rabbit anti-human CLDN 7 Polyclonal Abcam Ab27487 1:100
Rabbit anti-GFP Polyclonal Novus Biologicals, LLC NB-600-308 1:1000
Rabbit anti-rat Desmin Polyclonal AnaSpec, Inc. (San Jose, CA) 29593 1:200
Mouse anti-rat THY1/CD90 IgG1 Cedarlane (Hornby, ON, Canada) CL005AP 1:50
Mouse anti-rat THY1/CD90 IgG1 BD Biosciences (San Jose, CA) 553016 1:50
Mouse anti-rat THY1/CD90 IgG2a Antibody Solutions (Sunnyvale, CA) Ab53226 1:25
Mouse anti-CDH1 IgG2a Transduction Lab, BD Biosciences 61081 1:50
Mouse anti-CDH1 IgG1 ECM Biosciences (Versailles, KY) CM1681 1:50
Rabbit anti-GFP Polyclonal Novus Biologicals, LLC AB-4 1:500
Mouse anti-rat CD44 IgG2a Cedarlane CL044 1:50
Mouse OV6 IgG1 Kind gift from Dr. Stewart Sell
(Wadsworth Center, Albany, NY)
NA 1:50
Mouse anti-ACTA2 IgG2a Abcam Ab11003 1:100
Mouse anti-GFAP IgG1 Abcam Ab80842 1:400
Mouse anti-rat VCAM1 IgG1 Bio Legend (San Diego, CA) 200401 1:100
Rabbit anti-CD29/integrin B1 Monoclonal Epitomics (Burlingame, CA) 2288-1 1:50
Mouse anti-vimentin IgG1 Lab Vision Corporation (Fremont, CA) MS129-PO 1:50
Mouse anti-rat NT5E IgG1 BD Biosciences 551123 1:50
NA, not applicable.
Liu et al(Piscataway Township, NJ) (NA934V). Anti-mouse perox-
idaseeconjugated antibody was from Vector Laboratories
(Immpress Reagent Kit; MP-7422; Burlingame, CA). All
ﬂuorescent secondary antibodies were purchased from
Jackson Immunoresearch Laboratories (West Grove, PA)
and used at a dilution of 1:200: anti-mouse IgG (DyLight
549), number 715-505-151, subclass 1; anti-mouse IgG (cy2
conjugated, number 115-225-205), subclass 1; anti-mouse
IgG (cy3 conjugated, number 115-165-206), subclass 2a;
and anti-rabbit IgG (cy2 conjugated, number 715-165-151,
and DyLight 488, number 715-095-151).
Animals
Male Dpp4þ/þ F344 rats (8 to 10 weeks of age) were pur-
chased from Taconic Farms (German Town, NY). Female
mutant Dpp4/ F344 rats (cell transplantation recipients)
were provided by the Animal Models, Stem Cells and Cell
Therapy Animal Core of the Liver Research Center at the
Albert Einstein College of Medicine (Bronx, NY). Hetero-
zygous rats expressing green ﬂuorescent protein (GFP) under
the ubiquitin C promoter (line 307 F455 Chr5) were obtained
from Rat Resource and Research Center (University of
Missouri, Columbia, MO). The rats were bred to homozy-
gosity and used subsequently. All studies with animals were
conducted under a protocol approved by the Institute for
Animal Studies of the Albert Einstein College of Medicine in
accordance with NIH guidelines.33
Liver Injury Models
Two liver injury models were used: Rs/PH and 2-AAF/PH. In
the ﬁrst model, the rats received two i.p. doses of Rs, two112weeks apart, each of 30 mg/kg body weight. Four weeks after
the second dose of Rs, two-third PH was performed. Animals
(nZ 3 in each group) were sacriﬁced 1, 2, 3, and 4 months
after PH. In the second model, 2-AAF pellets (35 mg per
animal, 21-day release; Innovative Research of America,
Sarasota, FL) were implanted s.c. PHwas performed on day 7
after pellet insertion. Animals (n Z 3 in each group) were
sacriﬁced 2 weeks and 1, 2, 3, and 4 months after PH.
TBI and BMT
Total body irradiation (TBI) and bone marrow transplantation
(BMT) were performed as described previously.34 The rats
were transplanted through the tail vein with 5  107 freshly
isolated bone marrow cells from homozygous gfp-positive
F455 rats, 24 hours after TBI. In some experiments, rats were
injected i.p. with 30 mg/kg of busulfan and, 24 hours later,
transplanted through the tail vein with 5 107 freshly isolated
bone marrow cells from homozygous gfp-positive F455 rats.
Bone Marrow Reconstitution
Bone marrow reconstitution was determined in bone
marrow DNA of the recipient animals by PCR analysis,
following the genotyping protocol provided by the Rat
Resource & Research Center (Columbia, MO) for line 307
F455 Chr5 and using primers suggested by the company.
LWS 455 5, 50-AACCTCCCAGTGCTTTGAACGCTA-30
(forward) and 50-GGTGCCAAGCCTCAACTTCTTTGT-30
(reverse); and U3r-4, 50-ATCAGGGAAGTAGCCTTGTG-
TGTG-30. (LWS 455 5 forward and 5 reverse are on either
side of insertion on rat chromosome 5; U3r-4 is in the LTR
U3 region.)ajp.amjpathol.org - The American Journal of Pathology
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To determine the reconstitution of BM stromal cells with
GFPþ donor stromal cells, total bone marrow cells were
isolated, as described previously,34 and plated for propa-
gation in Dulbecco’s modiﬁed Eagle’s medium (DMEM)/
F12 medium containing 20% fetal bovine serum (FBS).
Hematopoietic cells were gradually removed from the dish
during cell washing. At 6 to 10 days after plating, cells were
lifted and collected on cytospins. The cells were then ﬁxed
in 2% paraformaldehyde, permeabilized with per-
meabilization buffer (eBiosciences, Inc., San Diego, CA),
treated with GFP and CD90 antibodies, and analyzed by
immunoﬂuorescence (IF) microscopy for expression of GFP
and CD90 using antibodies listed in Table 1. Because the
number of stromal cells is low (approximately 200,000 per
rat), bone marrow stromal cell reconstitution was deter-
mined by counting the number of total cells and GFPþ cells
on 10 slides.
Isolation of the Total NPC Fraction for FACS Analysis
and IF Microscopy
Isolation of hepatic nonparenchymal cell (NPC) was
described previously.20,35,36 After two-step perfusion of
the liver,37 the cell suspension was centrifuged for 10
minutes at 400  g. The pellet was suspended in 100 mL
of Leffert’s C solution containing 0.05% collagenase
(Collagenase Worthington Type 1; Worthington Bio-
chemical Corp., Freehold, NJ)) and 0.003% DNase. The
cell suspension was further digested for 30 minutes at
37C and 20 mL FBS was added. The cell suspension was
ﬁltered through 40-mm mesh and centrifuged for 30 sec-
onds at 50  g in the cold. The supernatant was centri-
fuged two more times for 1 minute at 50  g and then
centrifuged for 10 minutes at 300  g to pellet crude
NPC. The pellet was suspended in 100 mL ﬂuorescence-
activated cell sorter (FACS) buffer [4% FBS in
phosphate-buffered saline (PBS)] and centrifuged again
for 10 minutes at 300  g. The pellet was washed two
more times under the same conditions and ﬁnally sus-
pended in 80 mL PBS. The cell suspension was distrib-
uted in eight tubes on top of a discontinuous 25% and
50% Percoll gradient (in PBS) and centrifuged for 20
minutes at 1000  g in the cold. Viable hepatocytes were
pelleted to the bottom of the tubes. NPCs were collected
at the interphase between 25% and 50% Percoll. Cell
debris remained in the top layer. The NPCs were diluted
with FACS buffer and washed several times.
FACS Analysis of GFP-Positive and Thy1-Positive Cells
of the Liver
For FACS analysis of GFPþ cells, we used ﬂow cytometry
analyzer BD LSRII (BD Biosciences, San Jose, CA) and
software: FACSDiva version 6 (BD Biosciences) andThe American Journal of Pathology - ajp.amjpathol.orgFlowJo version 9.5 (Tree Star Inc., Ashland, OR). Live and
single cell populations were analyzed on the basis of scatter
and ﬂuorescence intensity.
Dead cells were labeled with Fixable Viability Dye
eFluor 780 (eBioscieces, Inc.), according to manufacturer’s
instructions, and then ﬁxed in 3.7% paraformaldehyde in
PBS. Before labeling with Thy1 antibody, the cells were
washed and suspended in FACS buffer. Thy1/CD90 anti-
bodies were as follows: mouse CD90 (IgG1), OX-7 (BD
Pharmingen, San Diego, CA) at dilution 1:100, and mouse
CD90 (IgG1), OX-7 (Cedarlane, Hornby, ON, Canada) at
dilution 1:100. Secondary antibody anti-mouse IgG
(DyLight 549), number 715-505-151 was from Jackson
Immunoresearch Laboratories (West Grove, PA) and used at
a dilution of 1:200. GFP in the cells was detected with GFP
antibody (Novus Biologicals, LLC, Littleton, CO) and anti-
rabbit IgG (cy2 conjugated, number 715-165-151, or
DyLight 488, number 715-095-151).
RT-PCR and Quantitative PCR
All reverse transcription reactions were performed with Su-
perScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA),
according to the manufacturer’s protocol. Rat-speciﬁc primers
for different genes were chosen with the Primer3 program
(http://bioinfo.ut.ee/primer3-0.4.0/primer3) (Table 2). The
expression level of glyceraldehyde-3-phosphate dehydroge-
nase gene (Gapdh) was used as an internal control (as
described previously).20,35,36
To quantify the expression of rat Thy1, Tnf, Epcam, and
Mki67 genes, SYBR Green assays were designed that
covered exon-exon junction areas. Primers were ordered
from Integrated DNA Technology (Coralville, IA); the se-
quences of primers and lengths of amplicons are presented
in Table 2. Rat Rpl27 gene was used as a reference gene
because it showed less variability between different samples
of same concentration than Gapdh. Real-time PCR was
performed in triplicate for each gene. Each SYBR Green
assay was performed in a 10-mL total reaction volume that
included 5 mL of 2 SYBR Green Power master mix
(Applied Biosystems, Foster City, CA), 300 nmol/L of each
primer in Thy1 and Epcam assays, 100 nmol/L of each
primer in Tnfa assay, 150 nmol/L of each primer in Mki67
assay, 200 nmol/L of each primer in Rpl27 assay, and 20 ng
of template cDNA. Assays were run on 7500FAST instru-
ment (Applied Biosystems, Foster City, CA) under the
standard conditions recommended by the manufacturer and
were as follows: 95C for 10 minutes, followed by 40 cycles
of 95C for 15 seconds, and 60C for 1 minute, followed by
melting curve analysis. Data were analyzed using the 7500
ABI software version 2.0.6. Fold difference of gene
expression was determined by DDCT method. Assays were
validated using ﬁvefold dilution control and few experi-
mental samples (ranging from 100 to 0.16 ng per reaction)
and showed a linear range of detection from 100 to 0.8 ng in
all assays with PCR efﬁciency 95% to 106%.113
Table 2 Primers Used in This Study
Primer name Primer sequence
Length of the
ampliﬁed DNA, bp NCBI accession number
Aat F: 50-AGAGTCCAACCTACCGTAAG-30
R: 50-TCTACGTGGAAGTCAGCATC-30
576 NM_022519
Afp F: 50-CGACATTTACATTGGACACTTG-30
R: 50-CTTTCTTCCTCCTGGAGATG-30
420 NM_012493
Alb F: 50-CATTCTGGTTCGATACACC-30
R: 50-GAAGTCACCCATCACCGTC-30
432 NM_134326
Activin A F: 50-TGAGGATGGTCTTCAGACTG-30
R: 50-GCACAGCCAGGAAGACACTG-30
520 NM_017128
Alcam F: 50-GCGGTTCTGATTCTGATTG-30
R: 50-TGATTTACATCGTGATCTGCG-30
443 NM_031753
Acta2 F: 50-TGTGCTGGACTCTGGAGATG-30
R: 50-TAGAGGTCCTTCCTGATGTC-30
429 NM_031004
CDH1 F: 50-GGAATCCTGTCCATGTATGTG-30
R: 50-GTTCTCACAGTTGATTGCAGTC-30
450 NM_031334
CD29 F: 50-GGTCAATCCGAAGTATGAGG-30
R: 50-AAAGCTGAGAATCAGTCATGG-30
396 NM_017022
CD44 F: 50-CAGATTCCAGAGTGGCTTATC-30
R: 50-CAGCTCCCAGTAATGACATG-30
353 NM_012924
CD73 F: 50-TGATAACGGTGTGGAAGGAC-30
R: 50-CTTCACGAATGGTGCTGTTC-30
590 NM_021576
CD105 F: 50-CTCAGGTTGCCAACGCTGCG-30
R: 50-CAGGACATAGGCCTCCTTGT-30
500 NM_001010968
Krt18 F: 50-ACAAGTACTGGTCTCAGCAG-30
R: 50-GCATGGAGTTGCTGGAGTC-30
405 NM_053976
Krt18 F: 50-ACATTCATGGACTCCGCAAG-30
R: 50-TGAGATTTGGGAGCATCCAC-30
187 NM_053976
Krt14 F: 50-CAGTTCACCTCCTCCAGCTC-30
R: 50-TATCCAGGTAGGTGGCCAAG-30
397 NM_001008751
Krt19 F: 50-CATTGACCTAGCCAAGATCC-30
R: 50-TGGTGTGAACTTTATCATGCC-30
548 NM_199498
Cldn7 F: 50-GTAGCATGCTCCTGGATTG-30
R: 50-CCAGCTCACACGTATTCCTTAG-30
240 NM_031702
Desmin F: 50-ATGTCCAAGCCAGACCTCAC-30
R: 50-AGGCCATCTTCACATTGAGC-30
400 NM_022531
Epcam F: 50-GGTGGTGTTAGCAGTCATTG-30
R: 50-ATCGTATTCTACTGTGGGCTG-30
472 NM_138541
Fn14 F: 50-CTCTGAACCGGCAATCATG-30
R: 50-GCTCCTCACTGGATCAGTG-30
390 NM_181086
Ggt F: 50-AATCATCGTGGATAAGGACG-30
R: 50-GCAGCATGTTCTCCAGAGTC-30
411 NM_053840
Gapdh F: 50-ATCCACTGGTGCTGCCAAG-30
R: 50-ATGTAGGCCATGAGGTCCAC-30
366 NM_017008
Gfap F: 50-CGCGTCTCAGTTGTGAAGG-30
R: 50-ACTGCTCTGAAGGTTAGCAG-30
426 NM_017009
Gp38 F: 50-CGCCTCTGGTACCAACACAG-30
R: 50-CGCCAATTATGATTCCGACC-30
228 NM_019358
Hgf F: 50-CATGAGAGAGGCGAGGAGAA-30
R: 50-AAGTCACCTTGCCTTGATGG-30
295 NM_017017
Icam F: 50-GGTTGGAGACTAACTGGATG-30
R: 50-GTCCAGTTCTGTGAAGCATG-30
395 NM_012967
Ifng F: 50-GCATGGATGCTATGGAAGG-30
R: 50-GGTGACAGCTGGTGAATCAC-30
310 NM_138880
Ifngr1 F: 50-GCACAGGCAGCTCCATATCT-30
R: 50-GGCAGGAGCTCATAGGTGAC-30
419 NM_053783
Il-1b F: 50-TACATCAGCACCTCTCAAGC-30
R: 50-AGATTCTTCTGTCGACAATGC-30
377 NM_031512
(table continues)
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Table 2 (continued )
Primer name Primer sequence
Length of the
ampliﬁed DNA, bp NCBI accession number
Il1r1 F: 50-ATTCGCAGCTGTCCTCTTAC-30
R: 50-TGTGCTCTTCAGCCACATTC-30
456 NM_013123
Il-6 F: 50-AGAGTCATTCAGAGCAATACTG-30
R: 50-TCATATTGCCAGTTCTTCGTAG-30
322 NM_012589
Klf4 F: 50-GCAGCTTGCAGCAGTAACAA-30
R: 50-CAGCAGTTCCTCGGGACTCA-30
750 NM_053713
Mki67 F: 50-TGTCACCTGAGCCAGTGAAG-30
R: 50-TGGGGAATCTCAGTCTGTCC-30
368 NM_001271366
C-met F: 50-GTCCACAGAGACTTAGCTGC-30
R: 50-TAGCATCACTTCATACAAGGC-30
351 NM_031530
Mcp1 F: 50-GCCAGATCTCTCTTCCTCCA-30
R: 50-AGGCATCACATTCCAAATCAC-30
494 NM_012603
C-Myc F: 50-GCTACGTCCTTCTCCCCAAGG-30
R: 50-TTCTTCAGAGTCGCTGCTGG-30
531 NM_012802
Pdgfra F: 50-GGCCCCATTTACATCATCAC-30
R: 50-GGAGTCATCATCCGAAAGGA-30
360 NM_031525
Pdgfrb F: 50-CAGCTGTCCTGAGGACAAAG-30
R: 50-TACCGTTGTGAGCAGTATTCC-30
400 NM_031525
Pdgfb F: 50-AGACTCCGTAGACGAAGATG-30
R: 50-TACTGTCTCACACTTGCAGG-30
400 NM_012673
Sox7 F: 50-TTCTGCCATTATGTCCACCTT-30
R: 50-ACTGGGCACCAGTCAATCAT-30
164 NM_001106045
Tat F: 50-TCTGCTATGGGGCACTGG-30
R: 50-GAGGAGGAGCGGTCCAGT-30
376 NM_012668
THY1 F: 50-AGCTATTGGCACCATGAAC-30
R: 50-TCACAGAGAAATGAAGTCCG-30
499 NM_012673
Tnfa F: 50-CTTCTGTCTACTGAACTTCGG-30
R: 50-TCCGTGATGTCTAAGTACTTG-30
512 NM_012671
Tgfa F: 50-CGCACGTACACACACCAAAC-30
R: 50-TCAGTGCATCATATACAGAAGTCAGAA-30
129 NM_021578
Tgfb1 F: 50-ATACGCCTGAGTGGCTGTCT-30
R: 50-TTCTCTGTGGAGCTGAAGCA-30
316 NM_001001513
Tweak F: 50-CATATTCCCGTTCTTCTGTAAC-30
R: 50-GAGGAGCTTGTCTCCATCTC-30
228 NM_012889
V-cam1 F: 50-CTCCAGATGTAGGTCAGAAC-30
R: 50-TAATCAGTATACCATGAATTAGG-30
239 NM_012889
Vimentin F: 50-CTTCGCCAACTACATCGACA-30
R: 50-CTGCAGCTCCTGGATCTCTT-30
400 NM_031140
Thy1* F: 50-AGCTATTGGCACCATGAACC-30
R: 50-GCTGATCACCCTCTGTCCTC-30
85 NM_012673
Epcam* F: 50-GTCATTGTCGTGGTGGTGTT-30
R: 50-TCAGCCTTCTCATATTTTGCTG-30
92 NM_138541
Tnfa* F: 50-GCTCCCTCTCATCAGTTCCA-30
R: 50-GCTTGGTGGTTTGCTACGAC-30
102 NM_012671
Mki67* F: 50-TGGGCTCCATTCTGTCTGAT-30
R: 50-CTGCTTTGCTGCATTCTGAG-30
140 NM_001271366.1
Rpl27* F: 50-GCAAGAAGAAGATCGCCAAG-30
R: 50-TCCAAGGGGATATCCACAGA-30
102 NM_022514.1
*These primers were used for quantitative RT-PCR.
F, forward; NCBI, National Center for Biotechnology Information; R, reverse.
Rat Liver Mesenchymal-Epithelial CellsIHC and IF Microscopy
Immunohistochemical (IHC) detection of antigens was per-
formed on frozen, paraformaldehyde-ﬁxed, sucrose-embedded
sections and parafﬁn-embedded sections. EndogenousThe American Journal of Pathology - ajp.amjpathol.orgperoxidase was inactivated for 30 minutes with 3% H2O2 in
methanol or for 5 minutes in 28 mg/mL of periodic acid, fol-
lowed by a 30-minute incubation in 1 mg/mL sodium boro-
hydride. Permeabilization of the cells for intracellular antigen
was for 15 minutes with 0.3% Triton X-100 in PBS or 1 hour in115
Figure 1 RT-PCR analysis of Thy1 (A), Tnf-a (B), Epcam (C), and Gapdh
(D) mRNA expression in normal and injured rat liver. Representative ani-
mals from four studied groups and time points were presented. 2-
acetylaminoﬂuorene (2-AAF), livers of two animals treated with 2-AAF
and sacriﬁced on day 7 after insertion of the tablet; 2-AAF/PH, six
different animals treated with 2-AAF in conjunction with PH and sacriﬁced
1 to 6 months after PH; NL, normal liver at 2, 4, and 24 months of age and
at 3 months after partial hepatectomy (PH); retrorsine (Rs), livers of two
animals sacriﬁced on day 30 after the second injection of Rs; Rs/PH, six
different animals treated with Rs in conjunction with PH and sacriﬁced 2 to
4 and 24 months after PH. The lengths of the amplicons are as follows: 500
bp for Thy1, 512 bp for Tnf-a, 411 bp for Epcam, and 366 bp for Gapdh.
Gapdh is used as an internal loading control (given in D).
Liu et alpermeabilization buffer (eBiosciences, Inc.). Blockingwaswith
2% donkey/goat/horse serum, 2% bovine serum albumin
(BSA), and 0.05% Tween 20.
Measuring Proliferation of Thy1-Expressing Cells
in Vitro
The cells were suspended in DMEM containing 2% serum
and plated at a concentration of 10,000 cells/100 mL in
triplicate for each mitogen in 96-well plates. On the next
day, the cells were deprived of serum and medium
substituted with DMEM/0.1% serum. After 48 hours, the
cells were washed and the medium replaced with 100 mL
DMEM, containing 0.1% serum and the cytokine/mitogen at
the respective concentrations. The assay was performed
after 30 hours with Quick Cell Proliferation Assay Kit II
(BioVision, Inc.), according to the manufacturer’s protocol,
and read at 450 nm on microtiter reader plate Epoch
(BioTech Instr Inc., Winooski, VT). This assay is based on
the cleavage of the tetrazolium salt to formazan by cellular
mitochondrial dehydrogenase.
Independently, we measured the proliferation of mesen-
chymal epithelial cells using the bromodeoxyuridine (BrdU)
Cell Proliferation ELISA Kit from Abcam (ab126556)
(Cambridge, MA), according to the manufacturer’s proto-
col. We followed the same protocol for activation of the
cells, as given above, and added BrdU during the last 20
hours of incubation. For these experiments, we used re-
combinant rat cytokines/mitogens whenever available.
Concentration of Cytokines and Mitogens
Final concentrations of cytokines and mitogens were as
follows: PDGF-BB, 10 and 20 ng/mL; IL-1a, 200 pg/mL, 1
ng, and 5 ng/mL; IL-1b, 5 ng and 10 ng/mL; IFN-g, 2 and
10 ng/mL; TNF-a, 1, 5, and 10 ng/mL; LPS, 10 and 100 ng/
mL; IL-6, 10 and 50 ng/mL; TGF-a, 10 ng/mL; TGF-1b, 1,
2.5, and 4 ng/mL; EGF, 10 ng/mL and 20 ng/nL; and HGF,
20 and 40 ng/mL.
Induction of Liver-Speciﬁc Genes in Thy1-Expressing
Cells in Vitro
Cells were plated in DMEM, containing 2% serum. On the
next day, the cells were placed in DMEM/1% serum. After
48 hours, the cells were washed and the medium replaced
with DMEM/0.1% serum and 40 ng/mL recombinant
human HGF. After another 48 hours, the cells were har-
vested and RNA isolated for RT-PCR analysis.
Statistical Analysis
Values were expressed as means  SD. Statistical signiﬁ-
cance was determined by Student’s t-test performed in
Microsoft Excel (Redmond, WA). P < 0.05 was considered
statistically signiﬁcant.116Results
Expression of Thy1 mRNA in Normal and Injured Rat
Liver
The RT-PCR analysis shows that in normal liver and in
normal liver after PH, Thy1 mRNA is weakly expressed
(Figure 1A). In the livers of rats treated with 2-AAF,
expression of Thy1 mRNA is already up-regulated in most
treated animals 7 days after insertion of the pellets (when
PH is performed). In Rs-treated animals, Thy1 mRNA
expression is also up-regulated in most animals 30 days
after the second injection (at the time of PH) (Figure 1A).
In rats exposed to the 2-AAF/PH protocol (21-day release
tablet), Thy1 mRNA expression was increased for up to 6
months after treatment (data are shown from representative
animals 1 to 6 months after PH) (Figure 1A). In Rs/PH rats,
expression of Thy1 mRNA did not return to normal level 2
years after treatment (Figure 1A). The real-time quantitative
PCR (qPCR) analysis showed that the expression level of Thy1
mRNA of 2-AAF/PH rats returned to normal in 6 months after
PH. However, it did not return to normal in Rs/PH-treated an-
imals 24 months after PH (Supplemental Figure S1). These
results indicate that a long-lasting inhibition of hepatocyte
proliferation imposed by Rs treatment32 leads to sustained and
protracted up-regulation of Thy1 mRNA expression.
TNF-a is a major proinﬂammatory cytokine, which af-
fects the production of other cytokines and growth factors. Itajp.amjpathol.org - The American Journal of Pathology
Rat Liver Mesenchymal-Epithelial Cellsplays an important role in OC-mediated liver regeneration.38
In normal liver, expression of Tnf-a mRNA is barely
detectable (Figure 1B). In animals receiving 2-AAF/PH,
expression of TNF-a mRNA was sharply increased for 2 to
3 months after PH, and declined at later time points
(whereas Thy1 mRNA expression was still up-regulated)
(Figure 1B and Supplemental Figure S1). The regular RT-
PCR showed increase of Tnf-a mRNA expression 2
months after PH (but not conﬁrmed by quantitative RT-
PCR) (Supplemental Figure S1). The obtained data suggest
that prolonged up-regulation of Thy1 mRNA is not under
the direct control of TNF-a.
The epithelial cell adhesion molecule (EPCAM) is a
typical surface marker of OC, although it is also expressed
in mature bile ducts.35 Expression of Epcam mRNA is
clearly up-regulated in the liver of 2-AAFetreated animals
on day 7 after insertion of the pellet and remains up-
regulated after PH in the course of 6 months, conﬁrmed
by the RT-qPCR data (Figure 1C and Supplemental
Figure S1). In animals treated according to the Rs/PH pro-
tocol, the increase of Epcam mRNA expression appears
early (at the time of PH) and remains elevated for 4 months
after exposure (Figure 1C and Supplemental Figure S1).
These data reveal that the expression of Thy1 mRNA
(expressed in mesenchymal cells surrounding OCs) and
Epcam mRNA (expressed in OCs themselves) increases and
decreases in parallel.
Additional data obtained for mRNA expression of Mki67
with RT-qPCR revealed that the proliferative activity in the
liver of 2-AAF/PH animals returned to normal in 4 months.
However, cell proliferation in the Rs/PH-treated rats con-
tinues in the course of 2 years after the treatment
(Supplemental Figure S1). These data clearly show that a
massive block of hepatocyte proliferation imposed by Rs
treatment results in a slow restoration of the liver.
Expression of Thy1 Protein in Normal and Injured Rat
Liver
As mentioned above, in normal liver, Thy1 is expressed in
cells in the periportal region, in ﬁbroblastic cells surrounding
biliary ducts, and in blood vessels (Figure 2A). We have
occasionally identiﬁed small clusters or single Thy1þ cells in
the liver lobules (Figure 2, B and D). The size and shape of
these cells vary: some are elongated, and others are roundish
and smaller (Figure 2C). We followed expression of Thy1
and caludin-7 (a marker of OCs previously described by our
laboratory35) in the livers of 2-AAFe and Rs-treated animals.
In the 2-AAFetreated rats, at the time of partial resection, an
increase in the number of Thy1-expressing cells was evident
(Figure 2, E and F); an increase in the number of OCs
expressing claudin-7 was also evident. In the Rs-treated
rats, 1 month after partial resection, an increase in the num-
ber of Thy1-expressing cells and OCs was also evident
(Figure 2, G and H). In the 2-AAF/PHmodel of OC-mediated
liver regeneration, the number of Thy1-expressing cells,The American Journal of Pathology - ajp.amjpathol.orgsurrounding OCs, was high, from 10 days to 2 months after
PH (Figure 2, I and J). Four months later, the number of
Thy1þ cells and of OCs decreased (Figure 2, K and L). In the
Rs/PH model, both claudin-7þ cells and Thy1þ cells prolif-
erated during the ﬁrst 2 months, forming small clusters in the
liver lobule (Figure 2M). Three months after PH, the number
of Thy1þ cells was still high (Figure 2N). The number of
Thy1þ cells gradually decreased thereafter (Figure 2O).
However, 6 months after PH, there were still small clusters of
Thy1þ cells in liver parenchyma (Figure 2P).
Immunochemical detection of Thy1þ cells and OCs in
Rs-treated liver showed the same results. Three months after
PH, small numbers of few Thy1þ cells could be observed in
the portal region of the normal liver (Figure 2Q), but in the
Rs-treated liver 3 months after PH, clusters of Thy1þ cells
in the parenchyma could be easily detected (Figure 2R), as
well as an increased number of OCs (Figure 2T).
These data showing expression of Thy1 and claudin-7 in
the OC model of liver regeneration coincide well with the
analyses of mRNA expression of Thy1 and Epcam in the
corresponding livers (Figure 1). These data reveal also that
in normal rat liver, Thy1-expressing cells are heteroge-
neous in appearance. Thy1þ cells surrounding the bile
ducts and blood vessels and occasionally single cells in the
liver lobule are larger and elongated, resembling ﬁbro-
blasts. Most of the Thy1þ cells in the liver lobule are
smaller and round and frequently form clusters. These re-
sults also reveal that Thy1þ cells appear early after the
administration of the drug, which could represent activa-
tion of its expression in certain populations of cells or
proliferation of Thy1þ cells or both. If a stronger and long-
lasting inhibition of hepatocyte division is imposed (as is
the case with Rs/PH model),32 Thy1þ cells can be detected
in the liver for a much longer time.
Mixed Mesenchymal-Epithelial Phenotype of the Small
Thy1-Expressing Cells in the Liver Lobule
To understand the nature of the small Thy1þ cells in the
liver lobule, we studied expression of epithelial and
mesenchymal markers in these cells. The experiment was
conducted with normal liver. Some of the Thy1þ cells co-
express Krt18 (alias CK18), Cdh1, and desmin, which
was best demonstrated on cytospins of NPC (Figure 3,
AeC). However, as reported previously, these cells do not
express Acta2 (alias a-Sma) (data not shown). The small
cells with mesenchymal-epithelial phenotype co-expressing
Krt18 and Cdh1, Cdh1 and desmin, and Krt18 and desmin
were frequently identiﬁed in the NPC fraction of normal
liver (Figure 3, DeF). To conﬁrm that some of the
mesenchymal-epithelial cells in normal liver that express
Krt18, desmin, and Cdh1 also co-express Thy1, we per-
formed triple labeling of NPC. Co-expression of Thy1,
Cdh1, and Krt18 is clearly documented in Figure 3, GeJ.
Co-expression of Krt18, Cdh1, and desmin is presented in
Figure 3, KeN, and co-expression of Thy1, Cdh1, and117
Liu et aldesmin in Figure 3, OeR. These data demonstrated the
presence of a small population of mesenchymal-epithelial
cells in normal rat liver that express all four markers. It
has to be emphasized, however, that only a small portion of
NPCs revealed this mixed phenotype. To better estimate the
number of cells with this mixed phenotype, we counted
5000 NPCs on cytospins and determined the percentage of
double-labeled desminþ/Krt18þ and desminþ/Thy1þ cells.
In normal liver, approximately 15% of NPCs express des-
min and <6% express Thy1. The cells that co-express
desmin and Krt18 are approximately 1.8%, and the num-
ber of those that co-express desmin and Thy1 is approxi-
mately 1.7%. This result showed that the cells with mixed
epithelial-mesenchymal phenotype are a subpopulation of
Thy1-expressing cells (<1.8% of NPCs).118Origin of Thy1-Expressing Cells in the Liver
To elucidate the origin of Thy1þ cells in the liver and of the
Thy1þ mesenchymal-epithelial cells, the possible involve-
ment of bone marrow was considered. The bone marrow of
whole bodyeirradiated rats or busulfan-treated rats was
reconstituted with bone marrow isolated from enhanced
GFP (EGFP)etagged rats, and the injured liver was
analyzed for the presence of GFPþ/Thy1þ double-positive
cells (as described in Materials and Methods). Bone
marrow DNA was analyzed on agarose gels for the presence
of amplicons characteristic for the gfp insertion (Figure 4A).
The results indicated that bone marrow DNA of the recip-
ient animals was mostly from GFP-positive cells [ie, high
levels of bone marrow reconstitution (85% to 100%) wereajp.amjpathol.org - The American Journal of Pathology
Rat Liver Mesenchymal-Epithelial Cellsachieved]. The GFPþ NPCs were easily detected in tissue
samples from the liver of irradiated and transplanted ani-
mals, using speciﬁc anti-GFP antibody (Figure 4, BeE).
To determine whether bone marrow stromal cells were
also substituted with donor cells expressing Thy1, recipient
bone marrow stromal cells were isolated and analyzed for
expression of GFP and co-expression of GFP and Thy1.
These experiments showed that stromal cells were also
efﬁciently substituted with GFPþ donor bone marrow cells
(Supplemental Figure S2A). However, because hematopoi-
etic cells do not adhere to the dish, they were efﬁciently
removed in 1 to 2 weeks during frequent washing and
changes of the medium. GFPþ bone marrow stromal cells
from chimeric animals were positive for Thy1, a charac-
teristic marker of mesenchymal stromal cells (Supplemental
Figure S2B). Almost 100% of bone marrow stromal cells
were GFPþ (Supplemental Figure S2C).
To quantify the presence of GFPþ cells in chimera rats, the
livers were perfused, NPCs were isolated, and the number of
GFPþ, Thy1þ, Thy1þ/GFPþ, and Thy1þ/GFP cells was
determined by FACS analysis (Figure 4F). These results
indicated that the NPC fraction of the livers of the recipient
animals contained 21% to 25% GFPþ cells (normal livers,
21%  1.6%; 2-AAFetreated livers, 24%  1.5%). [Most
GFPþ cells in chimeric livers were CD68þ macrophages/
Kupffer cells, CD45þ blood cells remaining in the liver after
perfusion, and CD31þ endothelial cells (D.L., M.I.Y., J.Z.,
A.A., M.D.D., unpublished results)]. We also conﬁrmed a
large increase of OC numbers in the chimeric livers in both
models of liver injury (data not shown). In normal liver,
Thy1-expressing cells were <6% of all NPCs (which in-
cludes ﬁbroblasts, blood progenitor cells, and mesenchymal-
epithelial cells). However, in the injured chimeric livers, this
number could reach 20% of the NPC fraction as all Thy1þ
cells expand. To directly test the possibility that Thy1þFigure 2 Detection of mesenchymal cells expressing Thy1 and hepatic progeni
2-acetylaminoﬂuorene (2-AAF) or retrorsine (Rs) in conjunction with partial hepat
Thy1 and Claudin-7 in tissue sections from normal liver and livers of rats treated
primary antibody and cy3-conjugated secondary antibody (red). Claudin-7 was st
antibody (green). Nuclei were visualized with DAPI (blue). Arrows point to Thy1-e
A: Periportal zone. B: Thy1-expressing ﬁbroblasts surround a bile duct, and other
Thy1-expressing cells in liver parenchyma display different sizes (arrows). C: Liv
cluster of Thy1-expressing cells in liver parenchyma at higher magniﬁcation (arro
rats at the time of PH. E and F: Liver section taken on day 7 after insertion of 2-AA
(arrowheads). G and H: Rs-treated liver, sacriﬁced 1 month after PH: groups of Th
IeL: Thy1- and claudin-7eexpressing cells in the liver of 2-AAF/PHetreated rat
animal 10 days after PH: expanding claudin-7þ oval cells (OCs) appear side by si
animal 2 months after PH: larger clusters of Thy1þ cells surrounding caludin-7þ
months (L) after PH: caludin-7þ OCs and Thy1þ cells are decreased compared with
Claudin-7eexpressing cells in the liver of Rs/PH-treated rats at different time p
expansion of small Thy1þ cells surrounding claudin-7þ pseudoduct (arrowhead)
months after PH: expansion of Thy1þ cells in the liver parenchyma (arrows) and al
months after PH: Claudin-7eexpressing pseudoducts (arrowheads) and Thy1þ c
expressing cells are still present in the liver parenchyma (arrows). QeT: IHC det
6 antibodies. Tissue sections from normal rat liver 3 months after PH (Q and S
Thy1 with alkaline phosphatase/Vector red (arrows; Q and R) and of OV-6 with
antibody depicts both ductular cells (labeled in S and T) and OCs (labeled in T, a
ted in the liver parenchyma (arrows). Original magniﬁcations: 20 (A, B, E, F, a
The American Journal of Pathology - ajp.amjpathol.orgmesenchymal cells appearing in the injured livers might
originate from the bone marrow, we determined the number
of double-labeled GFPþ and Thy1þ cells in chimeric livers.
In normal chimeras, the percentage of Thy1þ/GFP cells in
total NPC fraction was 4.9%  1.2%; and the percentage of
Thy1þ/GFPþ cells in the same fraction was 0.8%  0.3%.
Data from three 2-AAF/PHetreated animals, analyzed 2
weeks after PH, indicated that the percentage of Thy1þ/
GFP cells in the total NPC fraction was increased to
16.4% 3.0%, whereas the percentage of Thy1þ/GFPþ cells
increased to 1.8%  1.5%.
Figure 4G presents double labeling for GFPþ and Thy1þ
cells in chimeric livers of a control rat and rats treated with
2-AAF or Rs and then subjected to PH. Rare, double-
labeled cells could be detected in some ﬁelds. Cytospin
preparations of liver NPC from normal and 2-AAFetreated
chimeras were also analyzed. Normal liver contained single
Thy1þ/GFP and Thy1þ/GFPþ cells (Figure 4H). In 2-
AAF/PHetreated livers, the number of Thy1þ cells
increased signiﬁcantly, but not the number of double
(Thy1þ/GFPþ) labeled cells (Figure 4H). These ﬁndings
show that in both normal and injured rat liver, a small
portion of Thy1þ cells are of bone marrow origin and most
Thy1-expressing cells have hepatic origin.
Factors Activating Proliferation of Mesenchymal-
Epithelial Cells in Vitro
As demonstrated above, the number of mesenchymal-
epithelial cells in normal liver is low. To further charac-
terize these cells, we used single Thy1þ clones isolated in
our laboratory from 2-AAF/PHetreated rat liver. Some of
these cells yielded ﬁbroblastic clones, and others yielded
mesenchymal-epithelial clones.20 In this study, we used
mesenchymal-epithelial cell clones.tor cells expressing claudin-7 or OV-6 in normal livers and livers treated with
ectomy (PH). AeP: Double immunoﬂuorescence microscopy for detection of
with 2-AAF or Rs in conjunction with PH. THY1 was stained with anti-CD90
ained with antieclaudin-7 primary antibody and cy2-conjugated secondary
xpressing cells; arrowheads, claudin-7eexpressing cells. AeD: Normal liver.
Thy1-expressing ﬁbroblasts are scattered around blood vessels; clusters of
er parenchyma: Thy1þ cells with oval or round shape (arrows). D: Another
ws). EeH: Thy1- and claudin-7eexpressing cells in 2-AAFe and Rs-treated
F pellet: numerous claudin-7þ cells forming duct-like structures are evident
y1þ cells (arrows) are in close proximity to claudin 7þ cells (arrowheads).
s at different time points after PH. I: Liver section from a 2-AAFetreated
de with small Thy1þ cells (arrows). J: Liver section from a 2-AAFetreated
pseudoducts. Liver section from a 2-AAFetreated rat 4 months (K) and 6
earlier time points and have returned to background levels. MeP: Thy1- and
oints after PH. M: Liver section from a Rs-treated rat 2 months after PH:
; arrows point to Thy1þ cells. N: Liver section from a Rs-treated animal 3
so claudin-7þ cells (arrowheads). O: Liver section from Rs-treated animals 4
ells (arrows) are still present. P: At 6 months after PH, clusters of Thy1-
ection of Thy1 (red; Q and R) and OCs (red; S and T), with CD90 and OV-
) and from Rs-treated liver 3 months after PH (R and T). Visualization of
alkaline phosphatase/Vector red (arrowheads; S and T). Note that OV-6
rrowheads). R: In Rs/PH-treated livers, many Thy1 clusters can be detec-
nd IeN); 60 (C, D, G, and P); 40 (H and O); 10 (R).
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Figure 3 Co-expression of Thy1 with hepatic mesenchymal-epithelial cell markers in normal liver. AeF: Cytospins of isolated nonparenchymal cells analyzed
for expression of CD90, Krt18, Cdh1, and desmin. A: Co-expression of CD90 (green) and Krt18 (red). B: Co-expression of CD90 (green) and Cdh1 (red); some cells
express both antigens (arrow), and others express only Cdh1 (arrowhead). C: Co-expression of CD90 (green) and desmin (red) in a group of ﬁve cells. D: A group
of four cells positive for both Cdh1 (green) and Krt18 (red). E: Four cells co-expressing desmin (green) and Cdh1 (red) (arrows). F: A cluster of seven cells (arrows)
co-expressing desmin (green) and Krt18 (red). In the middle of the cluster, two cells are positive only for desmin (green). Nuclei are stained with DAPI. GeJ: Co-
expression of CD90, Cdh1, and Krt18 in isolated NPCs. Three cells are positive for CD90 (green; G), Cdh1 (red; H), and Krt18 (white, I). J:Merged image. KeN: Co-
expression of Cdh1, Krt18, and desmin in isolated NPCs. A cluster of cells expressing all three proteins: Cdh1 (red; K), Krt18 (green; L), desmin (white; M), and
merged image (N). (The sizes of the clusters in these panels were larger than those in DeJ. To include the entire clusters in the panels and keep the panels the
same size as in DeJ, it was necessary to electronically reduce the size of the panels in KeN for presentation, so that the size of the individual cells in KeN appears
smaller than in DeJ). OeR: Co-expression of CD90, Krt18, and desmin in isolated NPCs. O: Two cells express Cdh1 (red). The same cells express CD90 (green; P)
and desmin (white; Q); merged image (R). Original magniﬁcations: 40 (AeC); 60 (D, E, JeN, and PeR).
Liu et alBecause mesenchymal-epithelial cells proliferate in the
liver of 2-AAFe and Rs-treated rats, it is reasonable to
assume that speciﬁc growth factors and cytokines released
in these livers trigger the proliferation of mesenchymal-
epithelial cells. To address this issue, we studied the effect120of various cytokines and mitogens on the mesenchymal-
epithelial cell line 13-11-3-2, cloned and puriﬁed in our
laboratory from Thy1-expressing cells. Some of the factors
that were tested are predominantly mitogens for epithelial
cells (EGF, TGF-a, and HGF), and others for ﬁbroblastsajp.amjpathol.org - The American Journal of Pathology
Rat Liver Mesenchymal-Epithelial Cells(FGF 1, 2, and 3 and PDGF-BB). Cell proliferation was
assayed with the Quick Cell Proliferation Assay Kit II from
BioVision, Inc. (as described in Materials and Methods),
which provides the most sensitive method to quantify cell
proliferation and viability. This assay has been widely used
for measurement of cell proliferation in response to growth
factors, cytokines, mitogens, and nutrients. All tested cyto-
kines and growth factors stimulate the growth of 13-11-3-2
cells (Figure 5). Surprisingly, when the activity of the
different factors was compared, the most effective mitogens
for 13-11-3-2 cells were PDGF-BB and the inﬂammatory
cytokines, IL-1b and IFN-g; in fact, the activity of each of
these single cytokines exceeded that of 20% FBS (Figure 5).
To conﬁrm the proliferative response of mesenchymal
epithelial cells to different cytokines, we assayed the incor-
poration of BrdU into two cell lines: 13-11-3-2 and 13-11-3-5The American Journal of Pathology - ajp.amjpathol.orgusing the BrdU Cell Proliferation ELISA Kit from Abcam.
We also substituted some of the cytokines/mitogens with
available recombinant rat cytokines. These assays showed
that all cytokines/mitogens tested activate proliferation of 13-
11-3-2 cells. On the other hand, one cytokine, IFN-g, does
not affect proliferation of the 13-11-3-5 cell line
(Supplemental Figure S3). This difference could be attributed
to differences in the cell clones. An interesting observation
was that activation of proliferation depended on the con-
centration of serum added to the medium, when testing the
effect of cytokines. When this assay was performed using
control cells maintained in medium with 1% serum and even
0.5% serum, activation was much lower. Adding 20% serum
after 48 hours to control wells gave only 1.16% and 2.01%
activation of proliferation, respectively, suggesting that even
low serum concentration could partially mask the effect of
added cytokines/mitogens. These data also suggest that cells
that survive in 0.1% serum and are activated to proliferate on
addition of cytokines/mitogens maintain their survival by an
autocrine mechanism.
mRNA Expression of Growth Factors and Cytokines in
Mesenchymal-Epithelial Cell Clones
As shown above, proliferation of mesenchymal-epithelial
cells in vitro is highly stimulated by IFN-g, PDGF-BB, and
IL-1b. However, none of these mitogens is produced byFigure 4 Analysis of Thy1-positive cells in chimeric rat livers. A: Bone
marrow (BM) reconstitution of wild-type F344 rats with BM from F344-Tg
EGFP rats. Rats (numbers 86, 88, 94, and 93) received 11 Gy total body
irradiation and were transplanted with 5  107 BM cells from F344-Tg EGFP
rats. DNA isolated from the bone marrow of these animals was analyzed by
PCR with primers to detect the wild-type genome gfp (438-bp amplicon) or
the gfp insertion (129-bp amplicon); 35 cycles. The 524-bp amplicon cor-
responds to Gapdh mRNA; 28 cycles. BeE: Detection of GFPþ cells in
injured liver of chimeric rats. GFP-expressing cells were detected in
parafﬁn-embedded liver sections with GFP primary antibody and
peroxidase-conjugated secondary antibody, subsequently visualized by
diaminobenzidene (DAB). B: Chimeric animal 2 months after BMT. C:
Chimeric animal 2 months after BMT, treated with Rs/PH and sacriﬁced 1
month after PH. D: Chimeric animal 2 months after BMT treated with 2-AAF/
PH and sacriﬁced 2 weeks after PH. E: Liver section from normal wild-type
rat. F: FACS analysis of GFPþ and Thy1þ cells. Nonparenchymal cells (NPCs)
were isolated from the liver of chimeric rats. The x axis gives the green
ﬂuorescent intensity of live and single GFPþ cells; y axis, gives the red
ﬂuorescent intensity of CD90þ cells. Left panel: The percentage of CD90þ
NPCs. Right panels: The distribution of CD90þ cells between the GFPþ and
GFP populations. G: Co-expression of GFP and Thy1 in chimeric livers.
Expression of GFP (green) and Thy1(red) in tissue sections from chimeric
livers, detected by double IF microscopy: control chimeric rat, 2-
AAFetreated chimeric rat 1 month after PH, and Rs-treated chimeric rat
1 month after PH. Arrowheads point to cells expressing both markers. H:
Co-expression of GFP (green) and Thy1 (red) in NPCs isolated from chimeric
livers: cytospins of NPCs from normal chimeric liver and NPCs from 2-
AAFetreated chimeric liver 2 weeks after PH. GFP was visualized with
cy2, and Thy1 was visualized with cy3. Two cells in normal liver express
both antigens (arrowhead). In 2-AAF/PHetreated liver, most of the Thy1þ
cells are single labeled. Two cells expressing both antigens are labeled with
arrowheads. þ/, DNA from heterozygous animal; þ/þ, DNA from ho-
mozygous animal. Original magniﬁcations: 10 (E); 60 (G); 40 (H).
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Figure 5 Proliferation of mesenchymal-epithelial cell line 13-11-3-2
induced by different mitogens. The assay was performed using the Quick
Cell Proliferation Assay Kit II. The growth rate in 0.1% serum was taken
as a reference. The concentration of each mitogen is under the
respective column. Data represent means  SD of three independent
experiments.
Liu et almesenchymal-epithelial cells (Figure 6A), because none of
the respective mRNAs was expressed. By contrast, mRNAs
for these receptors are highly expressed (Figure 6A). The
above ﬁndings suggest that proliferation of Thy1 cells in
injured livers is sustained, at least in part, by the inﬂam-
matory cytokines IFN-g, PDGF-BB, and IL-1b released in
injured livers.
13-11-3-2 Cells express high levels of Tgfa, Hgf, Il6, and
Tnfsf12 (alias Tweak) mRNA (Figure 6B). The respective
proteins are mitogens for OCs. Surprisingly, the cells still
express these mRNAs if they are maintained in 1% FBS,
even 0.1% serum (data not shown). Furthermore, it is sig-
niﬁcant that the Hgf receptor Met and Tweak receptor
Tnfrsf12a (Fn14) mRNAs are also expressed in 13-11-3-2
cells (Figure 6A). The results of mRNA expression imply
that 13-11-3-2 cells maintain their own proliferation/self-
renewal by an autocrine mechanism and survive even in
low serum concentrations (Figure 5) and that they produce
growth factors and cytokines that are important for OC
proliferation (TGF-a, HGF, IL-6, and TWEAK).122Progenitor-Like Characteristics of Mesenchymal-
Epithelial Cell Lines
To analyze the mesenchymal-epithelial phenotype of 13-11-
3-2 cell line, expression of selected mRNAs was explored.
RT-PCR analysis showed that in addition to the cytokines
referred above, 13-11-3-2 cells express two types of genes:
typical mesenchymal genes and typical epithelial genes.
Typical mesenchymal genes are expressed in almost all
mesenchymal stem cells, including Eng (CD105), Alcam
(CD166), Itgb1 (CD29), Cd44, Nt5e (CD73), and Vcam1
(CD106), as well as other genes expressed in mesenchymal
cells, such as Pdpn (GP38), Des (Desmin), Icam1 (CD54),
Acta2 (a-SMA), Vim (Vimentin), and Inhba (Activin A)
(Figure 6C and Supplemental Table S1). IF microscopic
analysis conﬁrmed expression of CD29, CD44, CD73, CD106,
and Vimentin in these cells (Figure 7, A, G, I, K, and L). More
important, some of these genes (eg, Bmps, Gpc1, Gpc3, and
others) are not expressed in stellate cells or other ﬁbroblastic
cells of the liver, reinforcing the conclusion that mesenchymal-
epithelial cells have a peculiar phenotype, distinct from the
hepatic ﬁbroblasts and other mesenchymal cells.
Typical epithelial genes are abundantly expressed in liver
epithelial/ductular/OCs, including Cdh1, Krt18, Krt19,
Krt14, Epcam, and Cldn7 (Figure 6C and Supplemental
Table S1). IF microscopic analysis conﬁrmed the expres-
sion of CDH1, KRT18, OV-6, and Claudin 7 proteins
(Figure 7, D, E, J, and M). These genes are not expressed in
liver stellate or ﬁbroblastic cells.
In addition to mesenchymal stem cell markers and
epithelial cell markers, 13-11-3-2 cells and the other three
Thy1-expressing cell clones, isolated simultaneously with
13-11-3-2, revealed additional characteristics of stem/pro-
genitor cells. They expressed mRNA for classic stem cell
genes, such as Klf4 and Myc (Figure 6C). The 13-11-3-2
cells and the other mesenchymal cell lines that originated
from Thy1þ cells from 2-AAF/PHetreated livers could be
maintained for >3 years in culture (Figure 7, N and O). The
high plasticity of 13-11-3-2 cells was revealed in the pres-
ence of HGF and low serum concentration, as they begin to
express liver-speciﬁc genes, such as Alb, Afp, Serpina1
(alias Aat), and Sox7 (Figure 6D). The same result was
obtained with three other Thy1-expressing cell lines isolated
simultaneously with 13-11-3-2 (data not shown).
Induction of Thy1 Expression in Vitro
We noticed that the level of Thy1 mRNA expression varied.
When the cells were maintained in low serum concentration
(0.1%), Thy1 mRNA was low (Figure 8A). In the presence
of 1% serum, it increased and appeared even higher if the
cells were maintained in 20% serum (lanes 2 and 3) or in 1%
serum in the presence of the following cytokines: IL-6, IL-
1b, IFN-g, HGF, PDGF-BB, TGF-1b, TNF-a, and LPS (ie,
in the presence of the tested factors that increase prolifera-
tion of 13-11-3-2 cells). This result suggested thatajp.amjpathol.org - The American Journal of Pathology
Figure 6 RT-PCR analysis for expression of speciﬁc cytokine, growth factor, and receptor mRNAs in mesenchymal-epithelial cells. A: Expression of cytokine,
growth factor, and receptor mRNA. Cells were cultured in DMEM with addition of FBS at different concentrations: lane 1, 7 days in 0.1% serum; lane 2, 4 days in
1% serum; lane 3, 4 days in 10% serum; lane 4, 2 days in 20% serum. Note the lack of expression of Infg, Il1b, and Pdgfb mRNAs, whereas mRNAs for their
respective receptors (Ifngr1, Il1r, and Pdgfrb) are all present; Met and Tnfrsf12a mRNAs are also expressed. B: RT-PCR analysis for expression of OC mitogens
and epithelial cell markers in 13-11-3-2 cell line. Cells were cultured for 3 days in DMEM containing the following: lane 1, 1% FBS; lane 2, 20% FBS; lane 3, 1%
FBS þ 10 ng IL1B; lane 4, 1% FBS þ 10 ng IFN-g; lane 5, 1% FBS þ 10 ng PDGF-BB. Oval cells (OCs) mitogens (Hgf, Tnfsf12, Il6, Tgfa, Krt18, and Cdh1) were
expressed in 13-11-3-2 cells in all conditions tested. C: RT-PCR analysis for mesenchymal and epithelial-progenitor cell markers in 13-11-3-2 cell line. The cells
were maintained in DMEM, containing 2% serum for 2 days. RNA was isolated and RT-PCR analysis was performed to determine which mesenchymal and
epithelial cell markers were expressed. D: Induction of liver-speciﬁc gene expression in mesenchymal-epithelial cell lines. Cells were maintained for 24 hours in
DMEM/1% serum. Control cells from three different cell lines were transferred for 48 hours to DMEM/10% serum. RNA was isolated and expression of mRNAs for
key hepatocyte markers was tested by RT-PCR. Clone 13-11-3-2 expresses a low level of albumin mRNA; clone 13-11-3-3 expresses Afp mRNA, and clone 13-11-
3-5 expresses a very low level of both; 35 cycles. The induced 13-11-3-2 cells were washed and the medium replaced with DMEM, containing 0.1% serum and 40
ng/mL recombinant human HGF. RNA expression was analyzed 48 hours later. Note the expression of mRNAs for liver-speciﬁc genes and stem cell genes in
these cells; 30 cycles. [Two different pairs of primers were used for ampliﬁcation of Krt18 cDNA in normal and induced cells (Table 2)]. E: Hypothetical scheme
representing cross talk between the mesenchymal-epithelial cells and OCs. Mesenchymal-epithelial cells in rat liver are activated by inﬂammatory cytokines
(IFN-g, IL1, PDGFBB, and others), released in injured liver by Kupffer, stellate, NK, T, and NK T cells. The activated mesenchymal-epithelial cells then release
cytokines and growth factors, such as TGF, HGF, IL-6, and TWEAK, to induce or support growth of OCs (paracrine mechanism). Mesenchymal-epithelial cells also
express the receptors for these mitogens and self-maintain their growth by an autocrine mechanism.
Rat Liver Mesenchymal-Epithelial Cellsmesenchymal-epithelial cell proliferation is accompanied by
activation/induction of Thy1 expression.
We compared Thy1 expression in four mesenchymal-
epithelial cell lines (Figure 8B). Two of them (13-11-5 and
13-11-3) showed lower Thy1 expression. These two cell lines
grewmore slowly. The number of Thy1 cells in 1% serumwas
lower than in 10% serum. These data suggested that when
mesenchymal-epithelial cells proliferate, they express Thy1.
It has been shown that two distinct populations of ﬁbro-
blasts are present in rat lungs, Thy1þ and Thy1, and they
differ in their response to ﬁbrogenic agents.39 It was also
shown that Thy1 expression can be regulated in rat lungThe American Journal of Pathology - ajp.amjpathol.orgﬁbroblasts in vitro by the histone deacetylase (HDAC) in-
hibitor trichostatin A, pointing to an epigenetic regulation of
Thy1 expression.40
Valproic acid (VPA) is a novel inhibitor of multiple class
I and II HDACs,41,42 which induces differentiation of
transformed cells.43 We analyzed the effect of VPA on in-
duction of Thy1 expression in the mesenchymal-epithelial
13-11-1 cells that have discontinued expression of Thy1.
These cells expressed Pdpn (Figure 8C). In low serum
concentration, 2% FBS, 13-11-1 cells discontinued expres-
sion of Thy1 (Figure 8C). Under normal conditions for
propagation with 10% FBS, 13-11-1 cells showed a low123
Figure 7 Immunoﬂuorescence microscopy analysis for expression of mesenchymal and epithelial cell marker proteins in 13-11-3-2 cell line. Mesenchymal cell
markers were as follows: vascular cell adhesionmolecule 1 (VCAM;A); Desmin (B); ACTA2 (a smoothmuscle actin; C); glial ﬁbrillary acidic protein (GFAP; F); Vimentin
(G); Thy1 (CD90;H); CD73 (Ecto-50-Nucleotidase;K); and CD29 (Integrin b1; L); Epithelial cell markers were as follows: KRT18 (Cytokeratin 18;D); OV-6 (E); CD44 (I);
CDH1 (epithelial cadherin; J); CLDN7 (Claudin-7; M); phase-contrast microphotograph of cultured 13-11-3-5 cells (N); and phase-contrast microphotograph of
cultured 13-11-3-3 cells (O). Original magniﬁcations: 40 (M); 10 (N and O).
Liu et allevel of Thy1 expression (Figure 8C). When 2.5 mmol/L
VPA was added to the medium, expression of Thy1 was
markedly activated, even in a medium containing 2% FBS
(Figure 8C) and more so in 10% FBS (Figure 8D).
Induction of Thy1 expression in 13-11-1 cells was man-
ifested by IF microscopy using Thy1 antibody to detect the
protein. If cultured in normal medium, containing 2% or
10% FBS, Thy1 was almost undetectable in 13-11-1
(Figure 8D). After 5 days’ propagation in the same medium124containing 2.5 mmol/L VPA, there was a signiﬁcant in-
duction of the expression of Thy1 (Figure 8D).
Our results show that in certain mesenchymal-epithelial
cells, expression of Thy1 is inducible. This induction can be
achieved by soluble factors in the serum, by mitogens, and
also through epigenetic regulation, such as inhibition of
HDAC. The induction of Thy1 is reversible (ie, when the
cells are transferred to low serum concentration or VPA is
removed, expression of Thy1 drastically decreases).ajp.amjpathol.org - The American Journal of Pathology
Figure 8 Activation of Thy1 expression in vitro.A: RT-PCR analysis for Thy1mRNA expression in the presence of mitogens. 13-11-3-2 Cells weremaintained for 48
hours in DMEM/0.1% FBS. The mediumwas then changed as follows: lane 1, DMEM/0.1% FBS; lane 2, DMEM/1% FBS; lane 3, DMEM/20% FBS; lanes 4-11, cultured for
30 hours in DMEM/0.1% FBS in the presence of the following cytokines: lane 4, IL-6; lane 5, IL-1B; lane 6, IFN-g; lane 7, PDGFBB; lane 8, TGFB-1; lane 9, TNF-a; lane
10, HGF; lane 11, LPS. B: Immunoﬂuorescence microscopy analysis for Thy1 expression in mesenchymal epithelial cell lines. Four cell lines were plated in DMEM/2%
serum in two-well chambers. On the next day, the mediumwas replaced in one of the wells with DMEM/1% serum and in the second well with 10% serum. After 2 days,
the cells were harvested, ﬁxed in methanol, and processed for immunoﬂuorescence detection of Thy1. Thy1 was detected with anti-CD90 antibody and cy3 as
secondary Ab (red). Nuclei were labeled with DAPI (seeMaterials and Methods). C: RT-PCR analysis for mRNA expression of Thy1, Pdpn, and Gapdh. 13-11-1 Cells were
cultured as follows: lane 1, DMEM/10% FBS; lane 2, DMEM/2% FBS; lane 3, DMEM/10% FBS/2.5 mmol/L VPA; and lane 4, DMEM/2% FBS/2.5 mmol/L VPA. The length
of the Thy1 amplicon is 500 bp (see Materials and Methods). D: Immunoﬂuorescence microscopic analysis for Thy1 expression. Thy1 was detected with anti-CD90
antibody and cy3 as secondary Ab (red). Nuclei were labeled with DAPI. Cells were cultured as follows: DMEM/2% FBS, DMEM/2% FBS/2.5 mmol/L VPA, DMEM/2%
FBS, and DMEM/2% FBS/2.5 mmol/L VPA (see Materials and Methods). Original magniﬁcation: 60 (B); 20 (D).
Rat Liver Mesenchymal-Epithelial CellsDiscussion
Rat liver contains several cell types expressing Thy1 anti-
gen, including a small population of mesenchymal-epithelial
cells, which comprises 1.7% to 1.8% of NPCs of normal ratThe American Journal of Pathology - ajp.amjpathol.orgliver. The population of mesenchymal-epithelial cells
described in these studies has important features. Morpho-
logically, in quiescent liver, these cells are located in the
liver lobule and appear small and round. A deﬁning hall-
mark of this cell population is a dual mesenchymal-125
Liu et alepithelial phenotype. Decreased serum concentration leads
to higher expression of KRT18, KRT19, and CDH1, and the
cells shift to a more epithelial phenotype. However, under
growth-permissive conditions, they acquire a gene expres-
sion proﬁle that includes typical mesenchymal cell markers
[eg, CD105 (Endoglin), CD166 (Alcam), CD29 (Integrin
b1), and CD73 (Ecto-50-Nucleotidase)]. These cells behave
like mesenchymal-epithelial progenitors, because they ex-
press typical markers of mesenchymal progenitor cells and
liver epithelial progenitor cells.
The hepatic mesenchymal-epithelial cell clones obtained
fromThy1þ cells behave like stem/progenitor cells. Theywere
maintained for >3 years in culture. When seeded sparsely,
they form multiple clusters, reminiscent of stem cellelike
properties. They produce growth factors and cytokine mRNAs
(Hgf, IL-6, Tgfa, and Tnfsf12) and the corresponding re-
ceptors for these factors (eg, Met and Tnfrsf12a),20 even when
maintained in lower serum concentration, suggesting an
autocrine mechanism of self-support and self-renewal. By
using the most sensitive assay for cell proliferation from
BioVision, Inc., we found that three major inﬂammatory cy-
tokines, IFN-g, PDGF-BB, and IL-1, can trigger the activation
of Thy1 cells. In experimental models of OC-mediated liver
regeneration, both Thy1þ cells and OCs proliferate. Under
these conditions, a possible source of IFN-g is presented by
natural killer (NK) cells, T lymphocytes, and NK T cells.44
IFN-g can induce hepatocyte apoptosis or inhibit hepatocyte
cell cycle progression,45 whereas it is stimulatory for OC
proliferation.46 The results of our studies are consistent with
these observations: a possible scenario is, in fact, that IFN-g
activates proliferation of the mesenchymal-epithelial cells and
the latter cells, in turn, produce cytokines to target and activate
OCs (Figure 6E). Kupffer cells and stellate cells produce high
amounts of PDGF during stellate cell and myoﬁbroblast acti-
vation47,48; and this cytokine is also up-regulated after liver
injury.36 The results of our current studies indicate that PDGF-
BB is also involved in the activation of 13-11-3-2 cell
proliferation.
IL-1 is produced by activated macrophages and is an
important mediator of the inﬂammatory response. It is
involved in a variety of cellular activities, including cell
proliferation, differentiation, and apoptosis. The expression
of IL-1 and its receptor is rapidly induced in OC-mediated
liver regeneration in response to tissue damage and to
IFN-g.49,50 Because Thy1þ cells and OCs are activated and
proliferate simultaneously after liver injury, and the two cell
types appear in close contact, we previously suggested that
Thy1þ cells support OC proliferation and differentiation.20
This possibility is clearly demonstrated in the current study
by the ﬁnding that Thy1þ cells express mRNA for cytokines
and growth factors that are able to stimulate OC proliferation.
They also produce cytokines/mitogens that activate their own
proliferation. In addition, we found that Hgf, Ctgf, and re-
combinant rat cytokines Fgf-2, Tnf-a, and Il-1a (important
paracrine factors released in injured livers) also activated
proliferation of mesenchymal-epithelial cells. A hypothesis126consistent with our data is presented in Figure 6E. We hy-
pothesize that cytokines and mitogens released by Kupffer,
stellate, NK, T, and NK T cells in injured liver activate the
mesenchymal-epithelial cells; they begin to express Thy1
and proliferate. Mesenchymal-epithelial cells also maintain
their own proliferation/self-renewal by an autocrine mecha-
nism and survive even in low serum concentrations.
Mesenchymal-epithelial cells produce growth factors and
cytokines that trigger and maintain OC proliferation (TGFA,
HGF, Il-6, and TWEAK).
By reconstituting the bone marrow with GFP-tagged cells
and following the appearance of the GFP-positive cells in
the liver, we found that most Thy1-expressing NPCs in
untreated and 2-AAF/PHetreated rats were GFP negative
(ie, they are endogenous liver cells). A small fraction of
these cells are double-positive cells (Thy1þ/GFPþ) that
originate from the reconstituted bone marrow. On the basis
of these data, it is reasonable to conclude that when the liver
is injured, endogenous mesenchymal-epithelial cells are
activated, proliferate, and accumulate, whereas bone mar-
rowederived mesenchymal cells do not contribute signiﬁ-
cantly or only a small portion of them contribute to this
process (double-labeled GFPþ/Thy1þ cells were 0.8%,
Thy1þ-expressing cells were 6%, and mesenchymal-
epithelial cells were 1.7% to 1.8% of all NPCs).
Rat liver mesenchymal cells could be a product of
epithelial-to-mesenchymal transition. It has been shown that
primary cultures of adult liver cells undergo a change in
phenotype and gene expression toward mesenchymal
cells.30 However, recent studies by lineage tracing did not
reveal evidence of epithelial-to-mesenchymal transition of
hepatocytes, cholangiocytes, or epithelial progenitor cells in
murine models of hepatic ﬁbrosis.51,52 Although we cannot
completely rule out the possibility that the described cells
are a product of such a transition, this seems unlikely,
because Thy1þ cells appear and expand rapidly in the
injured liver in temporal association with OC activation and
proliferation.
Thy1 antigen has been also considered by some in-
vestigators as a marker of OCs themselves.12 Herein, we
show that Thy1 antigen is expressed in the small population
of mesenchymal-epithelial cells in the liver. When these
cells are activated, they express Thy1 and proliferate. Thy1
expression is inducible and proportional to the cell prolif-
eration. Recently, it was also shown in a mouse model of
liver progenitor cell activation that Thy1þ cells are not OCs,
but supporting cells producing FGF7.53 Recent evidence has
also been presented that most freshly isolated hepatic stem
cells from mouse embryonic liver co-express epithelial and
mesenchymal markers.54 Su et al55 established a human
liver bud-derived stem cell line, which expressed not only
genes speciﬁc to both mesenchymal cells and hepatic cells,
but also octamer-binding protein 4 (Oct4) and Nanog. Ev-
idence for the existence of a common progenitor precursor
of liver epithelial and mesenchymal cells was also reported
recently.56 These investigators established Scaþ murineajp.amjpathol.org - The American Journal of Pathology
Rat Liver Mesenchymal-Epithelial Cellsprogenitor cell lines from embryonic and newborn mouse
livers that co-expressed markers of epithelial and mesen-
chymal lineages. When transplanted into healthy livers,
these cells generated epithelial and mesenchymal liver-
speciﬁc cells: hepatocytes and hepatic stellate cells. It is
possible that the two cell types, Thy1þ-supporting cells and
Epcamþ OCs, that are activated and proliferate in adult rat
liver originate from a common mesenchymal-epithelial stem
cell precursor capable of differentiating along the two lin-
eages, depending on environmental clues.
Two types of mesenchymal Thy1 cells were identiﬁed in
fetal mouse liver.57 They are reminiscent of the two types of
mesenchymal Thy1 cells we have described in adult rat
liver. Morphologically, one population is cubical, whereas
the second is elongated with spindle shape. Furthermore, it
was reported that the ﬁrst type of Thy1þ cells expressed the
glycoprotein Gp38 and supported maturation and differen-
tiation of hepatoblasts, whereas the second type did not.57 In
fetal rat liver, it was found that rare Dlkþ hepatoblasts
expressed Thy1, but most Thy1þ cells were detected in the
Dlk population. When transplanted in normal rat liver in
conjunction with PH, Thy1þ fetal cells produce only rare,
small Dpp4þ cell clusters, few of which exhibited an hep-
atocytic phenotype. However, in Rs/PH-treated liver,
transplanted Thy1þ fetal cells achieved 4.6% to 23.5%
repopulation.58 We suggest that a few fetal stem/progenitor
mesenchymal-epithelial cells remain in adult liver in a
quiescent state. These cells are activated, proliferate, and
differentiate after injury to hepatocytes.
In conclusion, we have shown that adult rat liver harbors a
population of cells with mesenchymal-epithelial phenotype.
These cells have high plasticity, can be induced to express
liver-speciﬁc genes, and reveal characteristics of progenitor
cells. We propose that these cells are mesenchymal-epithelial
progenitors that remain in quiescent state in the liver during
development. They expand quickly after injury to hepato-
cytes and support OC-driven liver regeneration.Acknowledgment
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